What is Chardan Capital’s Forecast for NTLA FY2025 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at Chardan Capital reduced their FY2025 EPS estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Monday, November 18th. Chardan Capital analyst Y. Livshits now forecasts that the company will post earnings of ($4.14) per share for the year, down from their previous forecast of ($4.02). Chardan Capital currently has a “Buy” rating and a $91.00 price target on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.13) per share.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million during the quarter, compared to analyst estimates of $8.28 million. The firm’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.38) earnings per share.

NTLA has been the topic of several other research reports. William Blair reissued a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday. Stifel Nicolaus decreased their price objective on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Citigroup lowered their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Wedbush reiterated a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday. Finally, Barclays lowered their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Trading Up 5.7 %

NASDAQ:NTLA opened at $13.86 on Thursday. Intellia Therapeutics has a 12-month low of $12.82 and a 12-month high of $34.87. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -2.58 and a beta of 1.81. The company’s 50-day moving average is $18.26 and its two-hundred day moving average is $21.85.

Hedge Funds Weigh In On Intellia Therapeutics

A number of institutional investors have recently made changes to their positions in NTLA. SG Americas Securities LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at about $160,000. Vanguard Group Inc. lifted its holdings in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock worth $250,168,000 after buying an additional 746,263 shares during the last quarter. EntryPoint Capital LLC grew its position in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after acquiring an additional 1,563 shares in the last quarter. Axxcess Wealth Management LLC increased its holdings in shares of Intellia Therapeutics by 6.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock valued at $457,000 after acquiring an additional 1,010 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in shares of Intellia Therapeutics during the 1st quarter valued at approximately $303,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.20% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.